Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature.
Gabrielle ArbourBenjamin EllezamAlexander G WeilRomain CayrolMagimairajan Issai VananHallie ColtinValérie LaroucheCraig ErkerNada JabadoSébastien PerreaultPublished in: Neuro-oncology advances (2022)
Our patient had durable disease control with dabrafenib and trametinib. Given favorable responses reported in patients with HGG treated with BRAF inhibitors, we believe that upfront targeted therapy is a possible treatment approach that should be studied in the context of a clinical trial.